Lipocine Inc. (LPCN) vs NextCure, Inc. (NXTC)
A side-by-side comparison of Lipocine Inc. and NextCure, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
LPCN
Lipocine Inc.
$2.08HealthcareDelayed quote: Oct 6, 2026, 11:56 AM EDT
NXTC
NextCure, Inc.
$5.30HealthcareDelayed quote: Oct 6, 2026, 11:32 AM EDT
Total return — LPCN vs NXTC
growth of $100 · dividends reinvested · last 7yLPCN -93.3% (-32.1%/yr)NXTC -97.9% (-42.4%/yr)LPCN compounded faster over this window
LPCN NXTC
LPCN vs NXTC: by the numbers
- •NXTC is the larger company ($19M vs $17M market cap).
- •Both run net losses; NXTC's is the smaller (0.00% vs -755.13% net margin).
Metrics side by side
Valuation
| Metric | LPCN | NXTC |
|---|---|---|
| P/S ratio | 10.93 | N/A |
| P/B ratio | 0.79 | 1.58 |
Profitability
| Metric | LPCN | NXTC |
|---|---|---|
| Gross margin | -334.26% | 0.00% |
| Operating margin | -524.69% | 0.00% |
| Net margin | -755.13% | 0.00% |
| ROE | -54.45% | -351.86% |
| ROIC | -57.74% | -259.91% |
Growth (annualized)
| Metric | LPCN | NXTC |
|---|---|---|
| Total return CAGR (5Y) | -34.76% | -44.29% |
Frequently asked
- How have LPCN and NXTC total returns compared?
- Over the past 5 years, LPCN delivered -34.76% and NXTC delivered -44.29% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.